Influence of interleukin-6 (IL-6) autoantibodies on IL-6 binding to cellular receptors (Q41371647)

30 September 2017

title

Influence of interleukin-6 (IL-6) autoantibodies on IL-6 binding to cellular receptors (English)

1 reference

30 September 2017

1 reference

Hansen MB

1

1 reference

30 September 2017

Svenson M

2

1 reference

30 September 2017

Abell K

3

1 reference

30 September 2017

Yasukawa K

4

1 reference

30 September 2017

Diamant M

5

1 reference

30 September 2017

Bendtzen K

6

1 reference

30 September 2017

language of work or name

English

0 references

publication date

1 February 1995

1 reference

European Journal of Immunology

30 September 2017

published in

1 reference

30 September 2017

volume

25

1 reference

30 September 2017

issue

2

1 reference

30 September 2017

page(s)

348-354

1 reference

Soluble interleukin-6 receptor is released from receptor-bearing cell lines in vitro

30 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1002/EJI.1830250207

Interleukin 1, interleukin 6 and tumor necrosis factor in infection, inflammation and immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/EJI.1830250207

7 January 2021

Interleukin-6 in biology and medicine

1 reference

https://api.crossref.org/works/10.1002/EJI.1830250207

7 January 2021

Impaired immune and acute-phase responses in interleukin-6-deficient mice.

1 reference

https://api.crossref.org/works/10.1002/EJI.1830250207

7 January 2021

The role of interleukin-6 in mucosal IgA antibody responses in vivo

1 reference

https://api.crossref.org/works/10.1002/EJI.1830250207

7 January 2021

IgG1 plasmacytosis in interleukin 6 transgenic mice

1 reference

https://api.crossref.org/works/10.1002/EJI.1830250207

7 January 2021

Generation of plasmacytomas with the chromosomal translocation t(12;15) in interleukin 6 transgenic mice.

1 reference

https://api.crossref.org/works/10.1002/EJI.1830250207

7 January 2021

Interleukin 6: insights to its function in skin by overexpression in transgenic mice

1 reference

https://api.crossref.org/works/10.1002/EJI.1830250207

7 January 2021

Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6

1 reference

https://api.crossref.org/works/10.1002/EJI.1830250207

7 January 2021

Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody

1 reference

https://api.crossref.org/works/10.1002/EJI.1830250207

7 January 2021

Anticytokine strategies in the treatment of the systemic inflammatory response syndrome

1 reference

https://api.crossref.org/works/10.1002/EJI.1830250207

7 January 2021

Anti-interleukin-6 antibodies in normal human serum

1 reference

https://api.crossref.org/works/10.1002/EJI.1830250207

7 January 2021

Anti-interleukin-6 autoantibodies in rheumatic diseases. Increased frequency in the sera of patients with systemic sclerosis

1 reference

https://api.crossref.org/works/10.1002/EJI.1830250207

7 January 2021

High-affinity IgG autoantibodies to IL-6 in sera of normal individuals are competitive inhibitors of IL-6 in vitro

1 reference

https://api.crossref.org/works/10.1002/EJI.1830250207

7 January 2021

Binding of cytokines to pharmaceutically prepared human immunoglobulin

1 reference

https://api.crossref.org/works/10.1002/EJI.1830250207

7 January 2021

Autoantibodies to cytokines--friends or foes?

1 reference

https://api.crossref.org/works/10.1002/EJI.1830250207

7 January 2021

Purification and characterization of soluble human IL-6 receptor expressed in CHO cells

1 reference

https://api.crossref.org/works/10.1002/EJI.1830250207

7 January 2021

Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill

1 reference

https://api.crossref.org/works/10.1002/EJI.1830250207

7 January 2021

Sex- and age-dependency of IgG auto-antibodies against IL-1 alpha in healthy humans

1 reference

https://api.crossref.org/works/10.1002/EJI.1830250207

7 January 2021

Cloning and expression of the human interleukin-6 (BSF-2/IFN beta 2) receptor

1 reference

https://api.crossref.org/works/10.1002/EJI.1830250207

7 January 2021

Influence of tumour necrosis factor-alpha on the expression of Fc IgG and IgA receptors, and other markers by cultured human blood monocytes and U937 cells.

1 reference

https://api.crossref.org/works/10.1002/EJI.1830250207

7 January 2021

Inactivation of interleukin-6 in vitro by monoblastic U937 cell plasma membranes involves both protease and peptidyl-transferase activities

1 reference

https://api.crossref.org/works/10.1002/EJI.1830250207

7 January 2021

Phosphorylation of interleukin-6 at serine54: an early event in the secretory pathway in human fibroblasts

1 reference

https://api.crossref.org/works/10.1002/EJI.1830250207

7 January 2021

LIFR beta and gp130 as heterodimerizing signal transducers of the tripartite CNTF receptor

1 reference

https://api.crossref.org/works/10.1002/EJI.1830250207

7 January 2021

IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase

1 reference

https://api.crossref.org/works/10.1002/EJI.1830250207

7 January 2021

Cytokine signal transduction

1 reference

https://api.crossref.org/works/10.1002/EJI.1830250207

7 January 2021

Enhancement of interleukin 6 cytostatic effect on human breast carcinoma cells by soluble IL-6 receptor from urine and reversion by monoclonal antibody

1 reference

https://api.crossref.org/works/10.1002/EJI.1830250207

7 January 2021

Isolation of an mRNA encoding a soluble form of the human interleukin-6 receptor

1 reference

https://api.crossref.org/works/10.1002/EJI.1830250207

7 January 2021

The soluble interleukin-6 receptor is generated by shedding

1 reference

https://api.crossref.org/works/10.1002/EJI.1830250207

7 January 2021

Human recombinant dimeric IL-6 binds to its receptor as detected by anti-IL-6 monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1002/EJI.1830250207

7 January 2021

Analysis of interleukin 6 (IL-6)/IL-6 receptor system using monoclonal anti-IL-6 antibodies

1 reference

https://api.crossref.org/works/10.1002/EJI.1830250207

7 January 2021

Limited involvement of interleukin-6 in the pathogenesis of lethal septic shock as revealed by the effect of monoclonal antibodies against interleukin-6 or its receptor in various murine models

1 reference

https://api.crossref.org/works/10.1002/EJI.1830250207

7 January 2021

High amounts of circulating interleukin (IL)-6 in the form of monomeric immune complexes during anti-IL-6 therapy. Towards a new methodology for measuring overall cytokine production in human in vivo.

1 reference

https://api.crossref.org/works/10.1002/EJI.1830250207

7 January 2021

Increased circulating interleukin-6 (IL-6) activity in endotoxin-challenged mice pretreated with anti-IL-6 antibody is due to IL-6 accumulated in antigen-antibody complexes

1 reference

https://api.crossref.org/works/10.1002/EJI.1830250207

7 January 2021

Manipulating the Immune System with Immune Globulin

1 reference

https://api.crossref.org/works/10.1002/EJI.1830250207

7 January 2021

Identifiers

DOI

10.1002/EJI.1830250207

1 reference

30 September 2017

1 reference